Abstract
Measurements of plasma ADAMTS13 activity (ADAMTS13: AC) have been used for the diagnosis of patients with thrombotic thrombocytopenic purpura (TTP); however, the clinical usefulness of plasma ADAMTS13 antigen (ADAMTS13:AG) has been controversial, because antigen values vary widely among patients with acquired idiopathic TTP (ai-TTP). We have developed a novel enzyme-linked immunosorbent assay (ELISA) for the determination of plasma ADAMTS13:AG. This highly sensitive ELISA system using a neutralizing monoclonal antibody enables the detection of as little as 0.1 % of the level in normal human plasma, corresponding to approximately 1 ng/mL purified plasma ADAMTS13. The mean (± 2 SD) plasma level of ADAMTS13:AG in healthy individuals was 106.4% ± 39.3% (n = 52). Patients with Upshaw-Schulman syndrome (USS) (n = 20) and ai-TTP (n = 30) showed significantly reduced ADAMTS13:AG levels (0.5% ± 1.6% and 1.2% ± 3.4%, respectively). The ADAMTS13:AG level was 48.4% ± 42.6% in USS carriers (n = 40) and <8.3% in ai-TTP patients with <0.5% ADAMTS13:AC. These values were almost parallel to those for ADAMTS13:AC. This ELISA may be useful for the rapid determination of ADAMTS13: AG. Further investigations of this antigen would be helpful in advancing the understanding of the pathogenesis of congenital and acquired TTP.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Moake JL. Thrombotic microangiopathies. N Engl J Med. 2002;347:589–600.
Levy GG, Nichols WC, Lian EC, et al. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001;413:488–494.
Zheng XL, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K. Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem. 2001;276:41059–41063.
Soejima K, Mimura N, Hirashima M, et al. A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? J Biochem. 2001;130:475–480.
Plaimauer B, Zimmerman K, Volkel D, et al. Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood. 2002;100:3626–3632.
Furlan M, Robles R, Galbusera M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med. 1998;339:1578–1584.
Tsai HM, Lian ECY. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med. 1998;339:1585–1594.
Matsumoto M, Kokame K, Soejima K, et al. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome. Blood. 2004;103:1305–1310.
Scheiflinger F, Knöbl P, Trattner B, et al. Non-neutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura. Blood. 2003;102:3241–3243.
Rieger M, Ferrari S, Kremer-Hovinga JA, et al. Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy and patients with thrombotic microangiopathies (TMA). Thromb Haemost. 2006;95:212–220.
Feys HB, Liu F, Dong N, et al. ADAMTS-13 plasma level determination uncovers antigen absence in acquired thrombotic thrombocytopenic purpura and ethnic differences. J Thromb Haemost. 2006;4:955–962.
Vesely SK, George JN, Lämmle B, et al. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood. 2003;102:60–68.
Uemura M, Tatsumi K, Matsumoto M, et al. Localization of ADAMTS13 to the stellate cells of human liver. Blood. 2005;106:922–924.
Kato S, Matsumoto M, Matsuyama T, Isonishi A, Hiura H, Fujimura Y. Novel monoclonal antibody-based enzyme immunoassay for determining plasma levels of ADAMTS13 activity. Transfusion. 2006;46:1444–1452.
Ishizashi H, Yagi H, Matsumoto M, Soejima K, Nakagaki T, Fujimura Y. Quantitative Western blot analysis of plasma ADAMTS13 antigen in patients with Upshaw-Schulman syndrome. Thromb Res. 2006. In press.
Klaus C, Plaimauer B, Studt JD, et al. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura. Blood. 2004;103:4514–4519.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Yagi, H., Ito, S., Kato, S. et al. Plasma Levels of ADAMTS13 Antigen Determined with an Enzyme Immunoassay Using a Neutralizing Monoclonal Antibody Parallel ADAMTS13 Activity Levels. Int J Hematol 85, 403–407 (2007). https://doi.org/10.1532/IJH97.06210
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.06210